
Those of note were Glaxo SmithKline (GSK) with HPV vaccine, H1N1, seasonal flu vaccine, renal carcinoma, and lymphocyte leukemia.
Novartis (NVS) for H1N1, seasonal flu vaccine, MS, malaria, and schizophrenia.
Schering-Plough, now Merck (MRK) , for schizophrenia. Schering was bought out for their extensive drug pipeline of numerous upcoming drugs.
Sanofi-Aventis (SNY) had an antiarrhythmic drug, along with another flu vaccine for elderly patients. Sanofi is getting snuffed out with the Genzyme takeover bid but the bidding could still continue.
Others included Takeda Pharmaceuticals (TKPHF), Cypress Biosciences/Forest Labs, Allos Therapeutics, Lilly/Daiichi Sankyo, Gloucester Pharmaceuticals, and Theravance.